Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak

SARS-CoV-2 Pandemic Impact on Pediatric Emergency Rooms: A Multicenter Study

“…Acute communicable diseases represent the most common clinical conditions in children; in fact, up to 11 respiratory tract infections per year in infancy, 8 episodes per year at pre-school age, and 4 episodes per year at school age could be considered as normal [ 64 ]. Our results are also reinforced by several studies that have shown a reduction in the exacerbation of chronic conditions during lockdown period [ 65 ], such as asthma [ 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 ] and cystic fibrosis [ 74 ]. The reduction in total ER admissions can be also explained by parents’ fear of leaving their home and of being infected in the hospital [ 50 , 75 , 76 ], and the explicit order to avoid going to the ER unless in cases of extreme medical necessity [ 37 , 38 ].…”

Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy

“…Our study is amongst the largest of 6 published reports on patients with severe asthma treated with biologics and shows the worst outcome of COVID-19. The other studies in asthma patients on biologic treatment reported cases of COVID-19, but out of a total of 19 confirmed COVID-19 patients admitted to the hospital, only 2 were intubated, and 2 died [ 15 , [18] , [19] , [20] , [21] , [22] ]. Compared to these other studies, the COVID-19 cases in our study were clearly more severe.…”

“…In most studies COVID-19 asthmatics had mild to moderate disease, and only a few reports have been published on patients with severe asthma and COVID-19 [ 15 , [18] , [19] , [20] , [21] , [22] , [38] ]. A growing number of these patients with severe asthma use monoclonal antibodies targeting immune globulin E (IgE), IL-5, IL-5 receptor alpha (Rα) or IL-4Rα [ 23 ].…”

Association between asthma and clinical mortality/morbidity in COVID‐19 patients using clinical epidemiologic data from Korean Disease Control and Prevention

“…To the Editor, United States showed no association between asthma and severe disease, suggesting that it is still unclear whether asthma is a risk factor for a poor prognosis. [5][6][7] Given the variability in the reports analyzing the impact of underlying asthma on the prevalence and severity of COVID-19, there is a need to better characterize the relationship between asthma and Table S1). To assess the effect of asthma on the clinical morbidity due to COVID-19, the maximum morbidity score was obtained, and this score was used to calculate the EV for morbidity.…”